24/7 Market News Snapshot 12 August, 2025 – BioXcel Therapeutics, Inc. Common Stock (NASDAQ:BTAI)

August 12, 2025

DENVER, Colo., 12 August, 2025 (www.247marketnews.com) – (Nasdaq:BTAI) are discussed in this article.
BioXcel Therapeutics, Inc. (Nasdaq:BTAI) is witnessing a notable surge in its stock performance, with shares opening at $5.62 and rising to approximately $7.35, marking an increase of around 14.86%. The stock’s momentum is evidenced by a significant trading volume of 24.15 million shares, indicating robust investor interest. Having surpassed the previous session’s closing price of $6.40, the stock reflects a bullish sentiment among traders. Observers should note potential resistance levels near $7.50 to $8.00, while support is anticipated around $6.00. Ongoing evaluation of price action and trading volume will be crucial for gauging future market fluctuations.

In addition to its financial performance, BioXcel is actively advancing its clinical trial initiatives. The company recently announced the completion of its SERENITY At-Home Phase 3 trial, assessing the efficacy of BXCL501 for the acute treatment of agitation in individuals diagnosed with bipolar disorders and schizophrenia. The highly awaited topline results from this pivotal study are expected in August, with preliminary data suggesting a much larger target market than previously considered. This potential expansion could imply that millions of additional agitation episodes may be treated in home settings.

CEO Vimal Mehta, Ph.D., expressed enthusiasm regarding the forthcoming results, emphasizing the company’s commitment to enhancing patient care through innovative therapeutic approaches. BioXcel is also scheduled to meet with the FDA to discuss submissions pertinent to BXCL501, positioning itself to explore further regulatory opportunities for its currently marketed product, IGALMI®.

While the company’s financial results for the second quarter of 2025 reveal a net loss of $19.2 million alongside a $10.3 million investment in research and development, BioXcel’s strengthened cash position allows for robust investment in the advancement of its clinical programs. The recent publication of non-clinical data in Frontiers in Pharmacology also highlights BXCL501’s broader therapeutic applications. BioXcel remains steadfast in its mission to tackle psychiatric conditions, leveraging advanced technologies to foster better patient outcomes. The company’s future endeavors hold considerable promise as it continues to contribute to the field of neuroscience therapeutics.

Related news for (BTAI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.